文献速递临床免疫分子诊断

降钙素与降钙素原Elecsys免疫分析法在甲状腺髓样癌中的临床性能

Clinical performance of calcitonin and procalcitonin Elecsys® immunoassays in patients with medullary thyroid carcinoma.
PubMed 文献 · Clin Chem Lab Med · 2020-10-22

该研究评估了Elecsys降钙素(CT)和降钙素原(PCT)免疫分析法在甲状腺髓样癌(MTC)诊断中的性能。研究纳入活动性MTC、非活动性MTC及非MTC甲状腺疾病患者血清样本,发现活动性MTC的CT和PCT中位值显著高于其他组,且PCT在CT假阳性患者中不可测,提示PCT可作为高灵敏特异的替代标志物。

要点

  • 活动性MTC患者CT和PCT中位值显著高于非活动性MTC及非MTC甲状腺疾病患者。
  • PCT在5例CT假阳性的非MTC患者中不可测,有助于排除活动性MTC。
  • Elecsys PCT assay可作为高灵敏特异的替代MTC标志物,尤其适用于CT阳性患者。

核心结论

  • Elecsys PCT assay是高灵敏且特异的替代MTC标志物,阴性PCT可可靠排除活动性MTC。

研究设计与样本

  • 收集16例活动性MTC、23例非活动性MTC、125例非MTC良性甲状腺疾病和62例非MTC甲状腺癌患者的血清样本。
  • 同时使用Cobas e601平台上的Elecsys CT和PCT免疫分析法进行检测。

主要发现

  • 活动性MTC的CT和PCT中位值分别为94 pmol/L和1.17 ng/mL,显著高于非活动性MTC(0.28 pmol/L和0.06 ng/mL)及非MTC良性(0.37 pmol/L和0.06 ng/mL)或恶性(0.28 pmol/L和0.06 ng/mL)甲状腺疾病。
  • 5例非MTC患者CT结果假阳性,但其PCT不可测。

临床怎么用

  • PCT可作为MTC的补充或替代标志物,尤其对于CT阳性患者,阴性PCT有助于排除活动性MTC。
  • 同一自动化平台同时提供CT和PCT检测,便于实施反射策略以优化实验室诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Medullary thyroid carcinoma (MTC) is caused by a malignant transformation in the parafollicular C-cells of the thyroid, where calcitonin (CT) is released. Nowadays, CT is the main tumor marker used in the diagnosis and follow-up of MTC patients. Nonetheless, procalcitonin (PCT) has recently been proposed as a useful complementary/alternative biomarker in MTC. Our aims were to investigate the diagnostic performance of CT and PCT and their combination in the differential diagnosis between active and inactive MTC and between MTC and non-MTC thyroid diseases, respectively. METHODS: Serum samples were collected from 16 patients with active (i.e. primary tumour before surgery or post-surgical recurrent disease) and 23 with inactive (i.e. complete remission) MTC, 125 patients with non-MTC benign thyroid disease and 62 patients with non-MTC thyroid cancers, respectively. Elecsys® CT and PCT measurements were simultaneously performed on the Cobas e601 platform (Roche Diagnostics, Rotkreutz, Switzerland). RESULTS: Both CT and PCT median values in active MTC (94 pmol/L and 1.17 ng/mL, respectively) were significantly higher compared with inactive MTC (0.28 and 0.06) and either benign (0.37 and 0.06) or malignant (0.28 and 0.06) non-MTC. Undetectable PCT was found in five non-MTC patients with false positive CT results. CONCLUSIONS: Elecsys® PCT assay is a highly sensitive and specific alternative MTC marker. At the very least it appears useful in patients with positive CT results as negative PCT values securely exclude active MTC. The availability of both markers on the same automated platform facilitates reflex or reflective strategies to refine the laboratory diagnosis.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Giovanella L, Fontana M, Keller F, et al. Clinical performance of calcitonin and procalcitonin Elecsys® immunoassays in patients with medullary thyroid carcinoma. Clin Chem Lab Med. 2020. PMID: 33085633. doi:10.1515/cclm-2020-1424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。